Chan K, Roberts SA, Klimczak LJ, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47(9):1067-72. doi:10.1038/ng.3378
Stachler MD, Taylor-Weiner A, Peng S, et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet. 2015;47(9):1047-55. doi:10.1038/ng.3343
Van Allen EM, W Y Lui V, Egloff AM, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015;1(2):238-44. doi:10.1001/jamaoncol.2015.34
Lal D, Pernhorst K, Klein KM, et al. Extending the phenotypic spectrum of RBFOX1 deletions: Sporadic focal epilepsy. Epilepsia. 2015;56(9):e129-33. doi:10.1111/epi.13076
Onengut-Gumuscu S, Chen WM, Burren O, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47(4):381-6. doi:10.1038/ng.3245
Majumder B, Baraneedharan U, Thiyagarajan S, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:6169. doi:10.1038/ncomms7169
Evrony GD, Lee E, Mehta BK, et al. Cell lineage analysis in human brain using endogenous retroelements. Neuron. 2015;85(1):49-59. doi:10.1016/j.neuron.2014.12.028
International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects. Nature. 2010;464(7291):993-8. doi:10.1038/nature08987
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87. doi:10.1056/NEJMoa1409405
Hong YS, Kim J, Pectasides E, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014;9(10):e109440. doi:10.1371/journal.pone.0109440